Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The ...

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

A COLCHESTER pharmacy boss is “delighted” to offer a weight loss drug which has been used by celebrities through a new ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...

Studies have shown GLP-1 medications have other health benefits, including lowering the risk of certain diseases and addictions, like drinking and smoking.

On Friday, the US Food and Drug Administration announced drugs Wegovy and Ozempic by Novo Nordisk are no longer in shortage.

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...

We recently published a list of Top 10 Stocks to Buy According to Sustainable Insight Capital Management. In this article, we ...

Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is ...